Aggressive B-cell lymphoma with dual surface immunoglobulin light-chain expression.
Dual surface immunoglobulin light-chain expression in B-cell malignant neoplasm is a rare event, and has been predominantly reported in chronic lymphocytic leukemia. Herein, we report a case of aggressive B-cell lymphoma with kappa/lambda-dual surface immunoglobulin light-chain expression of a 69-year-old woman. The lymphoma cells were positive for CD5, CD19, CD20, HLA-DR, Ig kappa and Ig lambda. Southern blot analysis confirmed rearranged bands for both light chains with a monoclonal heavy chain rearrangement. She was treated with a combination of rituximab and CHOP regimen, but died of the progressive disease. To our knowledge, this is the first case of aggressive B-cell lymphoma showing dual kappa/lambda expression; the possible mechanisms of abnormal light chain expression are discussed.
Fujiwara
Tohru
T
Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine, Sendai. fujiwara-t@mail.tains.tohoku.ac.jp
Ishizawa
Kenichi
K
Kohata
Katsura
K
Yamamoto
Joji
J
Yamada
Minami F
MF
Kameoka
Junichi
J
Ichinohasama
Ryo
R
Harigae
Hideo
H
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000096:biosynthesis*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D011239:Prednisolone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage